Katerina Sidiropoulou

Ms. Katerina Sidiropoulou

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 February 2024 in Medicina
Verified
Journal Article
Open access
PDF file
Konstantinos TigkiropoulosKonstantinos Tigkiropoulos
Konstantinos Tigkiropoulos
SNSpyridon Nikas
Spyridon Nikas
MAManolis Abatzis-Papadopoulos
Manolis Abatzis-Papadopoulos
KSKaterina Sidiropoulou
Katerina Sidiropoulou
KSKyriakos Stavridis
Kyriakos Stavridis
NSNikolaos Saratzis
Nikolaos Saratzis
Background: Prospective single and multicenter studies have shown improved outcomes of patients who underwent carotid artery stenting with the novel CGuard dual-layer mesh stent at 1 year. Objectives: The aim of this study is to conduct a systematic review and meta-analysis of all published studies to assess 1-year efficacy and outcomes of CGuard in patients with carotid stenting. Methods: A systematic search was performed. All studies enrolling at least 20 patients were included in our analysis. The primary endpoints were death (all-cause, cardiovascular and ipsilateral stroke-related death) and stroke rate at 1 year. The secondary endpoint was in-stent restenosis at 1 year. Results: The final analysis included 1709 patients. The one-year all-cause mortality rate was 2.97% (39/1699, 95% CI: 1.26–6.86%, I2 = 67%, t2 = 0.3442, p < 0.01), cardiovascular-related death was 0.92% (10/1616, 95% CI: 0.35–2.39%, I2 = 34%, t2 = 0.2302, p = 0.18), and ipsilateral stroke-related death was 0.3% (1/1649, 95% CI: 0.1–0.87%, I2 = 0%, t2 = 0, p = 0.69). The one-year ipsilateral stroke rate was 1.21% (16/1649, 95% CI: 0.58–2.5%, I2 = 28%, t2 = 0.1433, p = 0.23), transient ischemic attacks (TIAs) rate was 1.78% (19/1149, 95% CI: 1.11–2.84%, I2 = 0%, t2 = 0, p = 0.69), and total composite 1-year stroke/TIA rate was 2.97% (32/1149, 95% CI: 1.84–4.77%, I2 = 0%, t2 = 0, p = 0.41). The in-stent restenosis rate at 1 year was 1.06% (13/1653, 95% CI: 0.48–2.34%, I2 = 28%, t2 = 0.2308, p = 0.22). Conclusions: This meta-analysis shows that CAS with CGuard is safe with minimal neurological adverse events and in-stent restenosis rate at 1 year.

24 December 2022 in Medicina
Verified
Journal Article
Open access
PDF file
Konstantinos TigkiropoulosKonstantinos Tigkiropoulos
Konstantinos Tigkiropoulos
MAManolis Abatzis-Papadopoulos
Manolis Abatzis-Papadopoulos
KSKaterina Sidiropoulou
Katerina Sidiropoulou
KSKyriakos Stavridis
Kyriakos Stavridis
DKDimitrios G. Karamanos
Dimitrios G. Karamanos
NSNikolaos Saratzis
Nikolaos Saratzis
Background and Objectives: Endovascular technologies have significantly improved the outcome of patients with critical limb ischemia (CLI). Drug eluting stents (DES) have documented their efficacy against percutaneous transluminal angioplasty (PTA) and bare metal stents (BMS) in infrapopliteal arterial occlusive disease. However, late in-stent neoatherosclerosis may lead to vascular lumen loss and eventually thrombosis. Polymer free DES constitute a new technology aiming to improve long term patency which their action is still under investigation. The purpose of this study is to report the mechanism of action and to provide a literature review of a novel polymer free amphilimus eluting stent (Cre8, Alvimedica, Instabul, Turkey) in infrapopliteal arterial disease. Methods: Publications listed in electronic databases, European Union Drug Regulating Authorities Clinical Trials Database, as well as scientific programmes of recent interventional vascular conferences were searched. Three studies were included. We analyzed primary and secondary patency, major amputation rate, freedom from CD-TLR, and mortality. Results: Cre8 was implanted in 79 patients with CLI. Most of the patients (n = 65) were Rutherford class 5–6 (82.3%), and diabetes mellitus (DM) was present in 66 patients (83.5%). Mean primary patency was 82.5% at 12 months. Mean lesion stented length was 20 mm and 35 mm in two studies. Mean limb salvage was 91.3% at 12 months. Freedom from CD-TLR was reported in two out of the three studies and was 96% and 83.8%. Mortality was 15% and 23.8% in the same studies, whilst it was not reported in one study. Conclusion: Stenting of infrapopliteal arteries with Cre8 is safe and feasible in patients with CLI and diabetes. All studies have shown very good primary patency and freedom from CD-TLR at 12 and 24 months. Larger observational prospective studies and randomized trials are necessary to establish long term effectiveness and clinical outcomes using the non-polymer Cre8 DES.

8 September 2025 in Annals of Vascular Surgery
Verified
Journal Article
Closed access
KSKaterina Sidiropoulou
Katerina Sidiropoulou
KTKonstantinos Tigkiropoulos
Konstantinos Tigkiropoulos
DCDanai Chatziathanasiou
Danai Chatziathanasiou
GCGeorgios Chatziantoniou
Georgios Chatziantoniou
AAAlexandros Apostolou
Alexandros Apostolou
NSNikolaos Saratzis
Nikolaos Saratzis

31 October 2026 in European Journal of Vascular and Endovascular Surgery
Verified
Journal Article
Closed access
KSKaterina Sidiropoulou
Katerina Sidiropoulou
ASAthanasios Saratzis
Athanasios Saratzis
CKChristos Karkos
Christos Karkos
KTKonstantinos Tigkiropoulos
Konstantinos Tigkiropoulos
NSNikolaos Saratzis
Nikolaos Saratzis
DKDimitrios Karamanos
Dimitrios Karamanos

17 April 2026 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
KSKaterina Sidiropoulou
Katerina Sidiropoulou
ASAthanasios Saratzis
Athanasios Saratzis
NSNikolaos Saratzis
Nikolaos Saratzis
Konstantinos TigkiropoulosKonstantinos Tigkiropoulos
Konstantinos Tigkiropoulos
CKChristos Karkos
Christos Karkos
DKDimitrios G. Karamanos
Dimitrios G. Karamanos
Background: Intravascular lithotripsy (IVL) has emerged as a novel vessel preparation device for patients with peripheral artery disease undergoing angioplasty. The IVL catheter includes an integrated balloon, which emits high pressure and transient sonic waves. The release of shockwaves results in cracking of intimal and medial calcium within the vessel wall improving lumen patency. Objectives: The aim of this prospective observational cohort study is to evaluate the morphological and imaging changes in atherosclerotic plaque in patients with PAD undergoing IVL as a vessel preparation technique, followed by angioplasty with drug-coated balloon (DCB) or stent placement if required. Secondary endpoint is to evaluate the efficacy of IVL in the perfusion of the lower extremities, by calculating the ankle–brachial index (ABI) and toe–brachial index (TBI) post-angioplasty, as well as adverse events within 30 days. Methods: Consecutive adult (≥18 years of age) patients with symptomatic femoropopliteal artery disease selected to undergo IVL will be included in the study. Computed tomography angiography (CTA) of the lower limbs will be performed pre- and postoperatively. Intraoperatively, an intravascular ultrasound (IVUS) will be used before and immediately post-angioplasty, for real-time evaluation of the morphological and quantitative changes in the atherosclerotic plaque. All participants will be clinically re-evaluated in 30 days postoperatively and a color Duplex ultrasound of the lower extremity arteries will be performed. The perfusion of the peripheral arteries will be assessed using ABI and TBI post-procedurally. Outcomes: The primary outcome is the quantitative assessment of changes in plaque morphology and volume within the index target lesion, based on pre- and post-procedural computed tomography angiography using TeraRecon™ (Durham, NC, USA) plaque analysis module, reflecting plaque modification and redistribution, in the context of IVL-based vessel preparation. Secondary outcomes include improvement of peripheral arterial perfusion and freedom from clinically driven target lesion revascularization (CD-TLR) and major adverse events.

22 July 2026 in Medicina
Verified
Journal Article
Open access
PDF file
Konstantinos TigkiropoulosKonstantinos Tigkiropoulos
Konstantinos Tigkiropoulos
KSKaterina Sidiropoulou
Katerina Sidiropoulou
GCGeorgios Chatziantoniou
Georgios Chatziantoniou
AAAlexandros Apostolou
Alexandros Apostolou
KSKyriakos Stavridis
Kyriakos Stavridis
NSNikolaos Saratzis
Nikolaos Saratzis
Background and Objectives: The Ankura stent graft was introduced in Europe in 2015 for the endovascular repair of infrarenal abdominal aortic aneurysms (AAAs). Evidence regarding its long-term efficacy remains limited. This study presents eight years of clinical experience with the Ankura endograft for endovascular aneurysm repair (EVAR) at a tertiary university vascular center. Materials and Methods: This single-center retrospective study included patients who underwent elective EVAR with the Ankura endograft between January 2015 and January 2023. All patients were anatomically suitable according to the instructions for use (IFU). Computed tomography angiography was performed at 1 and 12 months and annually thereafter during follow-up; the surveillance protocol was subsequently modified to use duplex ultrasound. Primary outcomes were categorized as early (technical success, clinical success, and 30-day mortality and morbidity) or late (aneurysm-related and non-aneurysm-related mortality). Results: A total of 220 patients were included (211 men [95.9%]); the mean age was 71.41 years (range, 49–87 years); and the mean aneurysm diameter was 59.15 mm (range, 32–109 mm). Primary and secondary technical success rates were 97.3% and 100%, respectively, and the clinical success rate was 96.8%. Thirty-day morbidity and mortality rates were 6.3% and 0%, respectively. No perioperative conversions occurred. The mean follow-up duration was 51.76 months (range, 1–131 months). Freedom from reintervention at 24, 36, 48, and 72 months was 98.2%, 97.7%, 97.2%, and 95.9%, respectively. Iliac limb patency was 99.5%. Aneurysm-related and non-aneurysm-related mortality during follow-up were 2.2% and 20.45%, respectively. Conclusions: In this study, the Ankura AAA stent graft demonstrated durable efficacy, with a high iliac limb patency rate, a low reintervention rate, and low aneurysm-related mortality during follow-up. Its long-term efficacy and safety should be evaluated in larger studies.